Compounds > dehydrocrenatidine
Page last updated: 2024-12-11

dehydrocrenatidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dehydrocrenatidine: a janus kinase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5318875
CHEMBL ID3400675
MeSH IDM000605771

Synonyms (17)

Synonym
inchi=1/c15h14n2o2/c1-4-10-15-13(12(19-3)8-16-10)9-6-5-7-11(18-2)14(9)17-15/h4-8,17h,1h2,2-3h
1-ethenyl-4,8-dimethoxy-9h-pyrido[3,4-b]indole
65236-62-6
dehydrocrenatidine
1-ethenyl-4,8-dimethoxy-9h-beta-carboline
DTXSID50415746
1-vinyl-4,8-dimethoxy-beta-carboline
CHEMBL3400675
AKOS032948581
FS-8922
4,8-dimethoxy-1-vinyl-9h-pyrido[3,4-b]indole
1-vinyl-4,8-dimethoxy-beta-carboline; 4,8-dimethoxy-1-vinyl-beta-carboline; 4,8-dimethoxy-1-vinylnorharman; 8-o-methylpicrasidine i; dehydrocrenatidine; kumujian g
o-methylpicrasidine i
B0005-146823
1-vinyl-4,8-dimethoxy--carboline; 4,8-dimethoxy-1-vinyl--carboline; 4,8-dimethoxy-1-vinylnorharman; 8-o-methylpicrasidine i; dehydrocrenatidine; kumujian g
CS-0024099
HY-N3710

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Cotreatment with dehydrocrenatidine and mitogen-activated protein kinase (MAPK) inhibitors indicated that dehydrocrenatidine induced apoptosis through the activation of extracellular signal-regulated kinases (ERK) and c-Jun N-terminal kinases (JNK)."( Apoptotic effects of dehydrocrenatidine via JNK and ERK pathway regulation in oral squamous cell carcinoma.
Chen, MK; Chuang, YC; Ho, HY; Hsieh, MJ; Lin, CC; Lo, YS, 2021)		1.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1194597Inhibition of PTP1B (unknown origin) assessed as inhibition rate at 100 uM2015Bioorganic & medicinal chemistry letters, May-01, Volume: 25, Issue:9
Canthinone alkaloids are novel protein tyrosine phosphatase 1B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (37.50)24.3611
2020's5 (62.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.76 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid
1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid: precursor of mutagenic nitroso cpd in soy sauce; structure given in first source		2.1110harmala alkaloid
nicotine
(S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.		7.41103-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
canthin-6-one
canthin-6-one: from Zanthoxylum usambarense; structure in first source. canthin-6-one : An indole alkaloid that is 6H-indolo[3,2,1-de][1,5]naphthyridine substituted by an oxo group at position 6.		2.1110enone;
indole alkaloid;
organic heterotetracyclic compound		antimycobacterial drug;
metabolite
1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid
1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid: structure given in first source; RN given refers to cpd without isomeric designation. 1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid : A member of the class of beta-carbolines that is 1,2,3,4-tetrahydro-beta-carboline substituted at position 3 by a carboxy group.		2.1110alpha-amino acid;
aromatic amino acid;
beta-carboline alkaloid		human urinary metabolite;
human xenobiotic metabolite;
plant metabolite;
rat metabolite
beta-carboline-3-carboxylic acid methyl ester
beta-carboline-3-carboxylic acid methyl ester: structure given in first source		2.1110beta-carbolines
5-methoxycanthin-6-one
5-methoxycanthin-6-one: isolated from Zanthoxylum chiloperone; structure in first source		2.1110alkaloid;
organic heterotetracyclic compound
Amalorin
[no description available]		2.1110alkaloid;
organic heterotetracyclic compound
Methyl nigakinone
4,5-dimethoxycanthin-6-one: an active metabolite of Picrasma quassiodes; structure in first source		2.1110beta-carbolines
1-acetyl-beta-carboline
1-acetyl-beta-carboline: structure in first source		2.1110harmala alkaloidmetabolite
harman
harman: a beta-carboline; RN given refers to parent cpd; structure. harman : An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A.		2.1110harmala alkaloid;
indole alkaloid fundamental parent;
indole alkaloid		anti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
nigakinone
nigakinone: an NSAID that may be useful in treating ulcerative colitis; structure in first source		2.1110beta-carbolines
1-Ethyl-9H-pyrido[3,4-b]indole
[no description available]		2.1110harmala alkaloid
beta-carboline-1-propionic acid
[no description available]		2.1110harmala alkaloid
1-methyl-beta-carboline-3-carboxylic acid
1-methyl-beta-carboline-3-carboxylic acid: metabolite from cows fed with corn silage; structure in first source		2.1110
9-methoxycanthin-6-one
9-methoxycanthin-6-one: from roots of Eurycoma longifolia (Simaroubaceae). 9-methoxycanthin-6-one : An indole alkaloid that is the 9-methoxy derivative of canthin-6-one. Isolated from Eurycoma longifolia and Simaba multiflora, it exhibits cytotoxic activity towards human cancer cell lines.		2.1110aromatic ether;
indole alkaloid;
organic heterotetracyclic compound		antineoplastic agent;
antiplasmodial drug;
metabolite
rk 682
[no description available]		2.1110
ConditionIndicatedRelationship StrengthStudiesTrials
Hepatocellular Carcinoma
[description not available]		02.8220
Cancer of Liver
[description not available]		02.8220
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.8220
Liver Neoplasms
Tumors or cancer of the LIVER.		02.8220
Carcinoma, Squamous Cell of Head and Neck
[description not available]		02.3110
Carcinoma, Epidermoid
[description not available]		02.3110
Squamous Cell Carcinoma of Head and Neck
The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.		02.3110
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.3110
Cancer of Head
[description not available]		02.3110
Invasiveness, Neoplasm
[description not available]		02.3110
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		02.3110
Nasopharyngeal Carcinoma
A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.		02.3110
Cancer of Nasopharynx
[description not available]		02.3110
Nasopharyngeal Neoplasms
Tumors or cancer of the NASOPHARYNX.		02.3110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2110
Allodynia
[description not available]		02.2110
Nerve Pain
[description not available]		02.2110
Neuralgia
Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.		02.2110